These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 15090013

  • 1. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A, Sadeghinia A, Faghihi G, Momeni A.
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T.
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G, Nilfroushzadeh MA, Iraji F.
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [Abstract] [Full Text] [Related]

  • 4. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R, Handjani F, Nouhpisheh MK.
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [Abstract] [Full Text] [Related]

  • 5. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
    Salmanpour R, Razmavar MR, Abtahi N.
    Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529
    [No Abstract] [Full Text] [Related]

  • 6. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A.
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R, Haftbaradaran E.
    BMC Complement Altern Med; 2007 Apr 27; 7():13. PubMed ID: 17466071
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Apr 27; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A, Janjua SA, Hussain I.
    Acta Dermatovenerol Croat; 2008 Apr 27; 16(2):60-4. PubMed ID: 18541100
    [Abstract] [Full Text] [Related]

  • 13. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 14. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A.
    Int J Dermatol; 2012 Oct 12; 51(10):1221-5. PubMed ID: 22994669
    [Abstract] [Full Text] [Related]

  • 15. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study.
    El-Sayed M, Anwar AE.
    J Eur Acad Dermatol Venereol; 2010 Mar 12; 24(3):335-40. PubMed ID: 19744259
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 12; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 20. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G, Nilforoushzadeh MA.
    Int J Dermatol; 2006 Jul 12; 45(7):819-21. PubMed ID: 16863518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.